A retrospective study of Octaplex in the treatment of bleeding in patients with haemophilia A complicated by inhibitors

Blood Coagulation and Fibrinolysis

Volumn 21, Issue 6, 2010, Pages 577-583

  Berntorp, Erik ^a   Figueiredo, Sandra ^b   Futema, Lucimara ^c   Pock, Katharina ^d   Knaub, Sigurd ^e   Walter, Olaf ^e   Trawnicek, Laurenz ^d   Römisch, Jürgen ^d  

^a LUND UNIVERSITY HOSPITAL   (Sweden)

^b Hemocentro da Paraíba ^*  (Brazil)

^c Octapharma Brazil Ltda   (Brazil)

^d Octapharma PPGmbH   (Austria)

^e Octapharma AG   (Switzerland)

Author keywords

bleeding episodes; bypassing agent; haemophilia A; inhibitors; Octaplex; prothrombin complex concentrate

Indexed keywords

OCTAPLEX; PROTHROMBIN; THROMBIN; UNCLASSIFIED DRUG;

ADULT; AREA UNDER THE CURVE; ARTICLE; BLEEDING; BLOOD SAMPLING; CLINICAL ARTICLE; CONTROLLED STUDY; DATA COLLECTION METHOD; DISEASE SEVERITY; DRUG COST; DRUG EFFICACY; DRUG SAFETY; EX VIVO STUDY; HEMOPHILIA A; HUMAN; IN VITRO STUDY; PRIORITY JOURNAL; RETROSPECTIVE STUDY; TREATMENT OUTCOME;

ADOLESCENT; ADULT; ANTIBODIES; BLOOD COAGULATION FACTORS; CHILD; DRUG EVALUATION; FACTOR IX; FACTOR VIII; HEMOPHILIA A; HEMORRHAGE; HUMANS; RETROSPECTIVE STUDIES; THROMBIN; TREATMENT OUTCOME; YOUNG ADULT;

EID: 77955918129     PISSN: 09575235     EISSN: None     Source Type: Journal    
DOI: 10.1097/MBC.0b013e32833c9ab9     Document Type: Article

References (29)

1. Astermark J, Donfield SM, DiMichele DM, Gringeri A, Gilbert SA, Waters J, Berntorp E. A randomized comparison of bypassing agents in hemophilia complicated by an inhibitor: the FEIBA NovoSeven Comparative (FENOC) study. Blood 2007; 109:546-551.
2. Ingerslev J. Hemophilia. Strategies for the treatment of inhibitor patients. Haematologica 2000; 85:15-20.
3. Kasper CK. Diagnosis and management of inhibitors to factors VIII and IX. World Federation of Hemophilia; 2004. vol 34. p. 1-22. www.wfh.org
4. Lusher JM. Inhibitor antibodies to factor VIII and factor IX: management. Semin Thromb Hemost 2000; 26:179-188.
5. Abildgaard CF, Britton M, Harrison J. Prothrombin complex concentrate (Konyne) in the treatment of hemophilic patients with factor VIII inhibitors. J Pediatr 1976; 88:200-205.
6. Lusher JM, Shapiro SS, Palascak JE, Rao AV, Levine PH, Blatt PM. Efficacy of prothrombin-complex concentrates in hemophiliacs with antibodies to factor VIII: a multicenter therapeutic trial. N Engl J Med 1980; 303:421-425.
7. Eyster ME, Spero JA, Catalano PM, Gill FM, Lusch CJ, Kajani MK, et al. Inhibitor treatment using unactivated prothrombin complex concentrates: the Pennsylvania experience - 1978-1982. Prog Clin Biol Res 1984; 150:309-322.
8. Lusher JM, Blatt PM, Penner JA, Aledort LM, Levine PH, White GC, et al. Autoplex versus proplex: a controlled, double-blind study of effectiveness in acute hemarthroses in hemophiliacs with inhibitors to factor VIII. Blood 1983; 62:1135-1138.
9. Sjamsoedin LJ, Heijnen L, Mauser-Bunschoten EP, van Geijlswijk JL, van HH, van AP, Sixma JJ. The effect of activated prothrombin-complex concentrate (FEIBA) on joint and muscle bleeding in patients with hemophilia A and antibodies to factor VIII. A double-blind clinical trial. N Engl J Med 1981; 305:717-721.
10. Hayashi T, Tanaka I, Shima M, Yoshida K, Fukuda K, Sakurai Y, et al. Unresponsiveness to factor VIII inhibitor bypassing agents during haemostatic treatment for life-threatening massive bleeding in a patient with haemophilia A and a high responding inhibitor. Haemophilia 2004; 10:397-400.
11. Franken T, Rees W, Hubner N, Albers J, Gansera B, Uhl M, et al. Octaplex in routine clinical use for prophylaxis and therapy of bleeding in patients with prothrombin complex factor deficiency [abstract]. Critical Care 2007; 11 (Suppl 2):376.
12. Lubetsky A, Hoffman R, Zimlichman R, Eldor A, Zvi J, Kostenko V, Brenner B. Efficacy and safety of a prothrombin complex concentrate (Octaplex) for rapid reversal of oral anticoagulation. Thromb Res 2004; 113:371-378.
13. Riess HB, Meier-Hellmann A, Motsch J, Elias M, Kursten FW, Dempfle CE. Prothrombin complex concentrate (Octaplex) in patients requiring immediate reversal of oral anticoagulation. Thromb Res 2007; 121:9-16.
14. Berntorp E, Salvagno GL. Standardization and clinical utility of thrombingeneration assays. Semin Thromb Hemost 2008; 34:670-682.
15. Dargaud Y, Beguin S, Lienhart A, Al DR, Trzeciak C, Bordet JC, et al. Evaluation of thrombin generating capacity in plasma from patients with haemophilia A and B. Thromb Haemost 2005; 93:475-480.
16. Hemker HC, Al DR, Beguin S. Thrombin generation assays: accruing clinical relevance. Curr Opin Hematol 2004; 11:170-175.
17. Luddington RJ. Thrombelastography/thromboelastometry. Clin Lab Haematol 2005; 27:81-90.
18. Reikvam H, Steien E, Hauge B, Liseth K, Hagen KG, Storkson R, Hervig T. Thrombelastography. Transfus Apher Sci 2009; 40:119-123.
19. Pock K, Heger A, Janisch S, Svae TE, Romisch J. Thrombin generation capacity is impaired in methylene-blue treated plasma compared to normal levels in single-donor fresh-frozen plasma, a licensed solvent/detergenttreated plasma (Octaplas) and a development product (Uniplas). Transfus Apher Sci 2007; 37:223-231.
20. Salvagno GL, Astermark J, Lippi G, Ekman M, Franchini M, Guidi GC, Berntorp E. Thrombin generation assay: a useful routine check-up tool in the management of patients with haemophilia? Haemophilia 2009; 15:290-296.
21. Santagostino E, Mancuso ME, Rocino A, Mancuso G, Scaraggi F, Mannucci PM. A prospective randomized trial of high and standard dosages of recombinant factor VIIa for treatment of hemarthroses in hemophiliacs with inhibitors. J Thromb Haemost 2006; 4:367-371.
22. Gomperts ED, Astermark J, Gringeri A, Teitel J. From theory to practice: applying current clinical knowledge and treatment strategies to the care of hemophilia A patients with inhibitors. Blood Rev 2008; 22 (Suppl 1): S1-11.
23. Kohler M. Thrombogenicity of prothrombin complex concentrates. Thromb Res 1999; 95:S13-S17.
24. Leissinger CA. Use of prothrombin complex concentrates and activated prothrombin complex concentrates as prophylactic therapy in haemophilia patients with inhibitors. Haemophilia 1999; 5 (Suppl 3):25-32.
25. Aledort LM. Comparative thrombotic event incidence after infusion of recombinant factor VIIa versus factor VIII inhibitor bypass activity. J Thromb Haemost 2004; 2:1700-1708.
26. Gilmore R, Harmon S, Keane G, Gannon C, O'Donnell JS. Variation in anticoagulant composition regulates differential effects of prothrombin complex concentrates on thrombin generation. J Thromb Haemost 2009; 7:2154-2156.
27. Ozelo MC, Villaca PR, De Almeida JO, Bueno TM, De Miranda PA, Hart WM, Karamalis M. A cost evaluation of treatment alternatives for mild-tomoderate bleeding episodes in patients with haemophilia and inhibitors in Brazil. Haemophilia 2007; 13:462-469.
28. Brummel KE, Paradis SG, Butenas S, Mann KG. Thrombin functions during tissue factor-induced blood coagulation. Blood 2002; 100:148-152.
29. Mann KG, Brummel K, Butenas S. What is all that thrombin for? J Thromb Haemost 2003; 1:1504-1514.